866-997-4948(US-Canada Toll Free)

Anemia - Pipeline Assessment and Market Forecasts to 2017

Published By :

GlobalData

Published Date : Nov 2010

Category :

Therapeutic Area

No. of Pages : 55 Pages


GlobalData, the industry analysis specialist, has released its new report, Anemia Pipeline Assessment and Market Forecasts to 2017. The report is an essential source of information and analysis on the global Anemia market. The report identifies the key trends shaping and driving the global Anemia market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Anemia sector. 

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDatas team of industry experts.

GlobalData valued the anemia market in 2009 at $10.4 billion, indicating a CAGR of 7.4% between 2001 and 2009. The main driver for the growth of the anemia market is the rapid utilization of Erythropoietin Stimulating Agents (ESAs) such as Aranesp (darbepoeitin alfa), Procrit (epoetin alfa), Epogen (epoetin alfa) and Neorecormon (epoetin beta). These therapies are biological in nature and the annual cost of anemia therapy with these drugs ranges between $3,000 and $8,000. The majority of these therapies were launched between 2001 and 2007 and as a result market growth was pronounced in that period. In 2007, safety concerns over the use of ESAs surfaced and this has led to a decline in sales of the drugs. Since then, growth in the anemia market has been declining. Between 2009 and 2017, the market is expected to decline further as there are no key promising therapies expected to enter the anemia market. Furthermore, biosimilars of ESAs have already entered the European market and are expected to enter the US market between 2009 and 2017. This factor is also expected to restrain the growth of the market. 

Scope

The report provides information on the key drivers and challenges of the Anemia market. Its scope includes:

  • Annualized global Anemia market revenues data from 2001 to 2009, forecast for eight years to 2017. 
  • Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as Erythropoesis Stimulating Agent, Oral HIF-PH inhibitor, TGFbeta inhibitors, Fetal globin gene expression stimulator, oral EPO inducers, EPO mimetic peptide.
  • Analysis of the current and future competition in the global Anemia market. Key market players covered are Amgen Inc, Roche, Jhonson & Jhonson, Vifor Inc, and Affymax.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. 
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Anemia therapeutics market.
Reasons to buy

The report will enhance your decision making capability. It will allow you to:

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline. 
  • Develop business strategies by understanding the trends shaping and driving the global Anemia market. 
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Anemia market in future. 
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. 
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. 
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. 
  • Whats the next big thing in the global Anemia market landscape? Identify, understand and capitalize
Table Of Content

1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 5

2 Anemia Market: Disease Overview 6
2.1 Overview 6
2.1.1 Macrocytic-normochromic anemia 6
2.1.2 Microcytic-hypochromic anemia 6
2.1.3 Normocytic-normochromic anemia 6
2.2 Signs and Symptoms 6
2.3 Severity of Anemia 7
2.4 Diagnosis 7
2.4.1 Physical Exam 7
2.4.2 Diagnostic Tests 7
2.5 Treatment 8
2.5.1 Dietary Changes and Supplements 8
2.5.2 Treatment with Medicines 8
2.5.3 Procedures 8

3 Anemia Market: Market Characterization 10
3.1 Overview 10
3.2 Anemia Market Size 10
3.3 Anemia Market Forecast and CAGR 12
3.4 Drivers and Barriers for the Anemia Market 13
3.4.1 Drivers for the Anemia Market 13
3.4.2 Restraints for the Anemia Market 13
3.5 Opportunity and Unmet Need 14
3.5.1 Impact Analysis of Unmet Needs 14
3.6 Key Takeaway 15

4 Anemia Market: Competitive Assessment 16
4.1 Overview 16
4.2 Strategic Competitor Assessment 16
4.3 Product Profile for the Major Marketed Products in the Anemia Market 17
4.3.1 Aranesp (darbepoetin alfa) 17
4.3.2 Procrit/Epogen/Eprex (epoetin alfa) 22
4.3.3 Venofer (iron sucrose injection, USP) 25
4.3.4 Mircera (methoxy polyethylene glycol-epoetin beta) 28
4.3.5 NeoRecormon (epoetin beta) 31
4.4 Key Takeaway 32

5 Anemia Market: Pipeline Assessment 34
5.1 Overview 34
5.2 Strategic Pipeline Assessment 34
5.2.1 Technology Trends Analytic Framework 34
5.3 Anemia Promising Drugs under Clinical Development 36
5.4 Molecule Profile for Promising Drugs under Clinical Development 36
5.4.1 Hematide (peginesatide) 36
5.5 Anemia Market Clinical Pipeline by Mechanism of Action 37
5.6 Anemia Pipeline Pipeline by Clinical Phases of Development 38
5.6.1 Anemia Regulatory Filing and Phase III Clinical Pipeline 38
5.6.2 Anemia Phase II Clinical Pipeline 39
5.6.3 Anemia Phase I Clinical Pipeline 39
5.6.4 Anemia Preclinical Pipeline 40
5.7 Discontinued / Suspended Drugs for Anemia 40
5.8 Key Takeaway 40

6 Anemia Market: Implications for Future Market Competition 41

7 Anemia Market: Future Players in the Anemia Market 42
7.1 Introduction 42
7.2 Affymax 42
7.2.1 Company Overview 42
7.2.2 Financial Performance 43
7.2.3 Anemia Pipeline Drugs 43
7.3 Amgen Inc 43
7.3.1 Company Overview 43
7.3.2 Business Description 43
7.3.3 Anemia Pipeline Drugs 44
7.4 Chugai Pharmaceutical 44
7.4.1 Company Overview 44
7.4.2 Financial Performance 44
7.4.3 Business Description 44
7.4.4 Anemia Pipeline Drugs 45
7.5 Hoffmann-La Roche 45
7.5.1 Company Overview 45
7.5.2 Business Description 46
7.5.3 Anemia Pipeline Drugs 46
7.6 Johnson & Johnson 46
7.6.1 Company Overview 46
7.6.2 Financial Performance 46
7.6.3 Business Description 47
7.6.4 Anemia Pipeline Drugs 48

8 Anemia Market: Appendix 49
8.1 Definitions 49
8.2 Scope of Pipeline Research 49
8.3 Acronyms 49
8.4 Research Methodology 50
8.4.1 Coverage 50
8.4.2 Secondary Research 51
8.4.3 Forecasting 51
8.4.4 Primary Research 54
8.4.5 Expert Panel validation 54
8.5 Contact Us 54
8.6 Disclaimer 54
8.7 Sources 55

List of Table


Table 1: Anemia Disease Severity, September 2010 7
Table 2: Anemia Market, Global, Treatment Options for Various Types of Anemia, September 2010 8
Table 3: Anemia Market, Global, Sales Value ($bn), 2001-2009 11
Table 4: Anemia Market, Global, Sales Value ($bn), 2009-2017 12
Table 5: Anemia Market, Global, Aranesp, Incidence of Adverse Effects in CRF Patients (%), 2010 19
Table 6: Anemia Market, Global, Aranesp, Incidence of Adverse Effects in Chemotherapy Patients (%), 2010 20
Table 7: Anemia Market, Global, Procrit, Incidence of Adverse Effects in CRF Patients (%), 2010 23
Table 8: Anemia Market, Global, Procrit, Adverse Effects in HIV-infected Patients Receiving Zidovudine, 2010 24
Table 9: Anemia Market, Global, Venofer, Incidence of Adverse Effects (%), 2010 26
Table 10: Anemia Market, Global, Mircera, Adverse Effects, 2010 30
Table 11: Anemia Market, Global, Marketed Products Comparison, February 2010 32
Table 12: Anemia Market, Global, Most Promising Drugs Under Clinical Development, September 2010 36
Table 13: Anemia Market, Global, Late-stage Development Pipeline, September 2010 38
Table 14: Anemia Market, Global, Phase II Clinical Development, September 2010 39
Table 15: Anemia Market, Global, Phase I Clinical Development, September 2010 39
Table 16: Anemia Market, Global, Preclinical Development, September 2010 40
Table 17: Anemia Market, Global, Terminated Drugs, September 2010 40
Table 18: Anemia Market, Global, Affymax, Anemia Pipeline, September 2010 43
Table 19: Anemia Market, Global, Amgen Inc., Anemia Pipeline, September 2010 44
Table 20: Anemia Market, Global, Chugai Pharmaceuticals, Anemia Pipeline, September 2010 45
Table 21: Anemia Market, Global, Hoffmann-La Roche, Anemia Pipeline, September 2010 46
Table 22: Anemia Market, Global, Johnson & Johnson, Anemia Pipeline, September 2010 48

List of Chart


Figure 1: Anemia Market, Global, Sales Value ($bn), 2001-2009 11
Figure 2: Anemia Market, Global, Sales Value ($bn), 2009-2017 12
Figure 3: Anemia Market, Global, Market Opportunity and Unmet Needs, 2009 15
Figure 4: Anemia Market, Global, Strategic Competitor Assessment of Major Marketed Products, 2010 17
Figure 5: Anemia Market, Global, Pipeline, Technology Trends Analytic Framework, 2010 35
Figure 6: Anemia Market, Global, Pipeline, Description of Technology Trends Analytic Framework, 2010 35
Figure 7: Anemia Market Clinical Pipeline by Mechanism of Action, September 2010 37
Figure 8: Anemia Market, Global, Pipeline by Phase of Clinical Development, 2010 38
Figure 9: Anemia Market, Global, Implications for Future Market Competition in the Anemia Market, 2010 41
Figure 10: Anemia Market, Global, Clinical Pipeline by Company, 2010 42
Figure 11: GlobalData Market Forecasting Model 53

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *